Show simple item record

dc.contributor.authorPrice, A
dc.contributor.authorYellowlees, A
dc.contributor.authorKeerie, C
dc.contributor.authorRussell, S
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorGilligan, D
dc.contributor.authorSnee, M
dc.contributor.authorSkailes, G
dc.contributor.authorHatton, M
dc.contributor.authorErridge, S
dc.contributor.authorMohammed, N
dc.date.accessioned2012-12-12T18:16:24Z
dc.date.available2012-12-12T18:16:24Z
dc.date.issued2012-09
dc.identifier.citationRadical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer. 2012, 77 (3):532-6 Lung Canceren_GB
dc.identifier.issn1872-8332
dc.identifier.pmid22672970
dc.identifier.doi10.1016/j.lungcan.2012.05.089
dc.identifier.urihttp://hdl.handle.net/10541/259197
dc.description.abstractPreclinical and phase I data suggest gemcitabine to be a potent radiosensitiser. This multicentre study addressed whether the addition of low dose gemcitabine to radical radiotherapy improved 2 year event-free survival in patients with medically inoperable stages I-II non-small cell lung cancer.
dc.language.isoenen
dc.rightsArchived with thanks to Lung cancer (Amsterdam, Netherlands)en_GB
dc.titleRadical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentEdinburgh Cancer Centre, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK.en_GB
dc.identifier.journalLung Canceren_GB
html.description.abstractPreclinical and phase I data suggest gemcitabine to be a potent radiosensitiser. This multicentre study addressed whether the addition of low dose gemcitabine to radical radiotherapy improved 2 year event-free survival in patients with medically inoperable stages I-II non-small cell lung cancer.


Files in this item

This item appears in the following Collection(s)

Show simple item record